Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 379

1.

Combination Therapy in Pulmonary Arterial Hypertension: Gleaning a Practical Approach from the Randomized Trials.

Booth DC.

Int J Angiol. 2019 Jun;28(2):93-99. doi: 10.1055/s-0039-1691791. Epub 2019 Jul 12.

PMID:
31384106
2.

Combination Therapy Improves Vascular Volume in Female Rats with Pulmonary Hypertension.

Lachant D, Meoli DF, Haight D, Staicu S, Akers S, Glickman S, Ambrosini R, Champion HC, White RJ.

Am J Physiol Lung Cell Mol Physiol. 2019 Jul 19. doi: 10.1152/ajplung.00450.2018. [Epub ahead of print]

PMID:
31322432
3.

A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension.

Zhang YJ, Wang N, Gu ZC, Wei AH, Cheng AN, Fang SS, Du HL, Wang LZ, Zhang GQ.

Cardiovasc Diagn Ther. 2019 Jun;9(3):239-249. doi: 10.21037/cdt.2019.03.02.

4.

Small Molecule IL-36γ Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis.

Todorović V, Su Z, Putman CB, Kakavas SJ, Salte KM, McDonald HA, Wetter JB, Paulsboe SE, Sun Q, Gerstein CE, Medina L, Sielaff B, Sadhukhan R, Stockmann H, Richardson PL, Qiu W, Argiriadi MA, Henry RF, Herold JM, Shotwell JB, McGaraughty SP, Honore P, Gopalakrishnan SM, Sun CC, Scott VE.

Sci Rep. 2019 Jun 24;9(1):9089. doi: 10.1038/s41598-019-45626-w.

5.

Pharmacokinetics of ambrisentan in a patient with Pulmonary Arterial Hypertension and a total gastrectomy.

Abston E, Farber HW.

Pulm Pharmacol Ther. 2019 Aug;57:101813. doi: 10.1016/j.pupt.2019.101813. Epub 2019 Jun 12.

PMID:
31199984
7.

Liver safety evaluation of endothelin receptor antagonists using HepatoPac® : A single model impact assessment on hepatocellular health, function and bile acid disposition.

Aleo MD, Ukairo O, Moore A, Irrechukwu O, Potter DM, Schneider RP.

J Appl Toxicol. 2019 Aug;39(8):1192-1207. doi: 10.1002/jat.3805. Epub 2019 May 27.

PMID:
31134659
8.

What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.

Li Q, Kuang HY, Wu YH, Lu TW, Yi QJ.

Medicine (Baltimore). 2019 May;98(20):e15632. doi: 10.1097/MD.0000000000015632.

9.

Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry.

Chazova IE, Arkhipova OA, Martynyuk TV.

Ter Arkh. 2019 Mar 10;91(1):24-31. doi: 10.26442/00403660.2019.01.000024.

PMID:
31090367
10.

Role of endothelin-1 clearance in the haemodynamic responses to endothelin-1 in the pulmonary and hindquarter vasculature of anaesthetised rats.

Angus JA, Wright CE.

Eur J Pharmacol. 2019 Jul 15;855:124-136. doi: 10.1016/j.ejphar.2019.05.009. Epub 2019 May 4.

PMID:
31063771
11.

A Phase I Study to Show the Relative Bioavailability and Bioequivalence of Fixed-Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects.

Okour M, Puri A, Chen G, Port K, Berni A, Khindri S, Schneider I, Tenero D.

Clin Ther. 2019 Jun;41(6):1110-1127. doi: 10.1016/j.clinthera.2019.04.007. Epub 2019 May 4.

PMID:
31060740
12.

Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan.

Tynan T, Hird K, Hannon T, Gabbay E.

J Int Med Res. 2019 May;47(5):2177-2186. doi: 10.1177/0300060519840130. Epub 2019 Apr 12.

13.

Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH).

Escribano-Subias P, Bendjenana H, Curtis PS, Lang I, Noordegraaf AV.

Pulm Circ. 2019 Apr-Jun;9(2):2045894019846433. doi: 10.1177/2045894019846433.

14.

A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis.

Schorpion A, Shenin M, Neubauer R, Derk CT.

BMC Rheumatol. 2018 May 15;2:13. doi: 10.1186/s41927-018-0021-z. eCollection 2018.

15.

Role of ambrisentan (selective endothelin-A receptor antagonist) on cigarette smoke exposure induced cognitive impairment in Danio rerio.

Muthuraman A, Nafisa K, Sowmya MS, Arpitha BM, Choedon N, Sandy CD, Rishitha N, Johurul I.

Life Sci. 2019 Apr 1;222:133-139. doi: 10.1016/j.lfs.2019.03.002. Epub 2019 Mar 4.

PMID:
30844374
16.

Pre-clinical assessment of a water-in-fluorocarbon emulsion for the treatment of pulmonary vascular diseases.

Ferguson SK, Pak DI, Hopkins JL, Harral JW, Redinius KM, Loomis Z, Stenmark KR, Borden MA, Schroeder T, Irwin DC.

Drug Deliv. 2019 Dec;26(1):147-157. doi: 10.1080/10717544.2019.1568621.

17.

High-risk pregnancy in a patient with pulmonary arterial hypertension due to congenital heart disease (PAH-CHD) with temporary shunt inversion and deoxygenation.

Hohmann C, Dumitrescu D, Gerhardt F, Kramer T, Rosenkranz S, Huntgeburth M.

Pulm Circ. 2019 Apr-Jun;9(2):2045894019835649. doi: 10.1177/2045894019835649.

18.

Microbial transformation of ambrisentan to its glycosides by Cunninghamella elegans.

Sponchiado R, Sorrentino JM, Olegário N, Oliveira SS, Cordenonsi LM, Silveira GP, Fuentefria AM, Mendez ASL, Steppe M, Garcia CV.

Biomed Chromatogr. 2019 Jun;33(6):e4496. doi: 10.1002/bmc.4496. Epub 2019 Feb 15.

PMID:
30663135
19.

Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review.

You R, Qian X, Tang W, Xie T, Zeng F, Chen J, Zhang Y, Liu J.

Can Respir J. 2018 Nov 18;2018:1015239. doi: 10.1155/2018/1015239. eCollection 2018.

20.

Isolation, identification, characterization, synthesis and quality control strategy of new process-related impurities in ambrisentan.

Feng WD, Zhuo SM, Zhang FL.

J Pharm Biomed Anal. 2019 Feb 20;165:325-337. doi: 10.1016/j.jpba.2018.12.008. Epub 2018 Dec 7.

PMID:
30579233

Supplemental Content

Loading ...
Support Center